keyword
MENU ▼
Read by QxMD icon Read
search

asparaginase allergy

keyword
https://www.readbyqxmd.com/read/27779086/genetic-predictors-of-drug-hypersensitivity
#1
José A Cornejo-García, Abderrahim Oussalah, Miguel Blanca, Rosa-María Guéant-Rodríguez, Cristobalina Mayorga, Julie Waton, Annick Barbaud, Francesco Gaeta, Antonino Romano, Jean-Louis Guéant
Our knowledge of genetic predisposing factors of drug hypersensitivity reactions (DHRs) is still scarce. The analysis of the genetic basis of these reactions may contribute to dissect the underlying mechanisms. We will outline current knowledge of the genetic predictors of most common DHRs, including reactions to betalactam antibiotics (BLs), nonsteroidal anti-inflammatory drugs (NSAIDs) and biological agents. The predictors of DHRs to BLs are mostly linked to IgE-class switching, IgE pathway and atopy (IL4R, NOD2, LGALS3) in replicated candidate gene studies, and to antigen presentation (HLA-DRA) in the single replicated GWAS performed so far...
September 27, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27376478/allergic-like-reactions-to-asparaginase-atypical-allergies-without-asparaginase-inactivation
#2
Robin Q H Kloos, Rob Pieters, Gabriele Escherich, Inge M van der Sluis
BACKGROUND: Asparaginase is an important component of pediatric acute lymphoblastic leukemia (ALL) therapy. Unfortunately, this treatment is hampered by hypersensitivity reactions. In general, allergies - regardless of severity - cause complete inactivation of the drug. However, we report atypical allergic reactions without inactivation of asparaginase, here called allergic-like reactions. PROCEDURE: Patients with an allergic-like reaction, who were treated according to the Dutch Childhood Oncology Group ALL-11 or the CoALL 08-09 protocol, were described...
November 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27151000/-comparison-of-the-effectiveness-and-safety-of-combined-chemotherapy-with-peg-asp-for-treatment-of-all-and-t-nhl-patients
#3
COMPARATIVE STUDY
Yan Xu, Jin Wang, Nan Yang, Ju Bai, Peng-Yu Zhang, Liu-Fang Gu, Bo Lei, Jie Liu, Fang-Xia Wang, Bing-Qiao Huang, Wang-Gang Zhang, Ai-Li He, Xing-Mei Cao, Yin-Xia Chen, Xiao-Rong Ma
OBJECTIVE: To explore the effectiveness and safety of combined chemotherapy with pegasparaginase (PEG-Asp) for treatment of patients with acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin's lymphoma (T-NHL) patients. METHODS: A total of 62 ALL or T-NHL patients were diagnosed and treated in our department and were enrolled in this study. Among them, 22 patients received the combined chemotherapy with PEG-Asp, while the other 40 patients received the standard chemotherapy with L-asparaginase (L-Asp) as the control...
April 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/26928249/consensus-expert-recommendations-for-identification-and-management-of-asparaginase-hypersensitivity-and-silent-inactivation
#4
Inge M van der Sluis, Lynda M Vrooman, Rob Pieters, Andre Baruchel, Gabriele Escherich, Nicholas Goulden, Veerle Mondelaers, Jose Sanchez de Toledo, Carmelo Rizzari, Lewis B Silverman, James A Whitlock
L-asparaginase is an integral component of therapy for acute lymphoblastic leukemia. However, asparaginase-related complications, including the development of hypersensitivity reactions, can limit its use in individual patients. Of considerable concern in the setting of clinical allergy is the development of neutralizing antibodies and associated asparaginase inactivity. Also problematic in the use of asparaginase is the potential for the development of silent inactivation, with the formation of neutralizing antibodies and reduced asparaginase activity in the absence of a clinically evident allergic reaction...
March 2016: Haematologica
https://www.readbyqxmd.com/read/26549586/intravenous-pegylated-asparaginase-versus-intramuscular-native-escherichia-coli-l-asparaginase-in-newly-diagnosed-childhood-acute-lymphoblastic-leukaemia-dfci-05-001-a-randomised-open-label-phase-3-trial
#5
RANDOMIZED CONTROLLED TRIAL
Andrew E Place, Kristen E Stevenson, Lynda M Vrooman, Marian H Harris, Sarah K Hunt, Jane E O'Brien, Jeffrey G Supko, Barbara L Asselin, Uma H Athale, Luis A Clavell, Peter D Cole, Kara M Kelly, Caroline Laverdiere, Jean-Marie Leclerc, Bruno Michon, Marshall A Schorin, Jennifer J G Welch, Steven E Lipshultz, Jeffery L Kutok, Traci M Blonquist, Donna S Neuberg, Stephen E Sallan, Lewis B Silverman
BACKGROUND: l-asparaginase is a universal component of treatment for childhood acute lymphoblastic leukaemia, and is usually administered intramuscularly. Pegylated Escherichia coli asparaginase (PEG-asparaginase) has a longer half-life and is potentially less immunogenic than the native Escherichia coli (E coli) preparation, and can be more feasibly administered intravenously. The aim of the Dana-Farber Cancer Institute Acute Lymphoblastic Leukaemia Consortium Protocol 05-001 (DFCI 05-001) was to compare the relative toxicity and efficacy of intravenous PEG-asparaginase and intramuscular native E colil-asparaginase in children with newly diagnosed acute lymphoblastic leukaemia...
December 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26376459/activity-and-toxicity-of-intravenous-erwinia-asparaginase-following-allergy-to-e-coli-derived-asparaginase-in-children-and-adolescents-with-acute-lymphoblastic-leukemia
#6
MULTICENTER STUDY
Lynda M Vrooman, Ivan I Kirov, ZoAnn E Dreyer, Michael Kelly, Nobuko Hijiya, Patrick Brown, Richard A Drachtman, Yoav H Messinger, A Kim Ritchey, Gregory A Hale, Kelly Maloney, Yuan Lu, Paul V Plourde, Lewis B Silverman
BACKGROUND: Erwinia asparaginase is antigenically distinct from E.coli-derived asparaginase and may be used after E.coli-derived asparaginase hypersensitivity. In a single-arm, multicenter study, we evaluated nadir serum asparaginase activity (NSAA) and toxicity with intravenously administered asparaginase Erwinia chrysanthemi (IV-Erwinia) in children and adolescents with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma with hypersensitivity to E.coli-derived asparaginase...
February 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/25987655/genome-wide-analysis-links-nfatc2-with-asparaginase-hypersensitivity
#7
Christian A Fernandez, Colton Smith, Wenjian Yang, Charles G Mullighan, Chunxu Qu, Eric Larsen, W Paul Bowman, Chengcheng Liu, Laura B Ramsey, Tamara Chang, Seth E Karol, Mignon L Loh, Elizabeth A Raetz, Naomi J Winick, Stephen P Hunger, William L Carroll, Sima Jeha, Ching-Hon Pui, William E Evans, Meenakshi Devidas, Mary V Relling
Asparaginase is used to treat acute lymphoblastic leukemia (ALL); however, hypersensitivity reactions can lead to suboptimal asparaginase exposure. Our objective was to use a genome-wide approach to identify loci associated with asparaginase hypersensitivity in children with ALL enrolled on St. Jude Children's Research Hospital (SJCRH) protocols Total XIIIA (n = 154), Total XV (n = 498), and Total XVI (n = 271), or Children's Oncology Group protocols POG 9906 (n = 222) and AALL0232 (n = 2163). Germline DNA was genotyped using the Affymetrix 500K, Affymetrix 6...
July 2, 2015: Blood
https://www.readbyqxmd.com/read/25740072/studies-on-deimmunization-of-antileukaemic-l-asparaginase-to-have-reduced-clinical-immunogenicity-an-in-silico-approach
#8
L N Ramya, Krishna Kanth Pulicherla
Protein therapeutics, particularly of heterologous origin are shown to elicit immunogenic responses which result in adverse allergic reactions in spite of their promising clinical benefit. L-Asparaginase is one such well known chemotherapeutic agent that has enhanced the survival rates to 90 % in the treatment of acute lymphoblastic leukaemia for past 30 years. But the use of this enzyme is accompanied by hypersensitive reactions ranging from allergy to anaphylactic shock which have a drastic influence in treatment outcomes...
September 2015: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/25697915/polymorphisms-in-gria1-gene-are-a-risk-factor-for-asparaginase-hypersensitivity-during-the-treatment-of-childhood-acute-lymphoblastic-leukemia
#9
Vladan Rajić, Maruša Debeljak, Katja Goričar, Janez Jazbec
l-asparaginase is an effective antineoplastic agent used in chemotherapy of acute lymphoblastic leukemia. The drug effect may be compromised by an elicited immune response, resulting in the production of anti-asparaginase antibodies causing an anaphylactic reaction or silent inactivation of the enzyme. To elucidate possible genetic predisposition for inter-individual differences in asparaginase hypersensitivity, we studied single nucleotide polymorphisms (SNPs) in the GRIA1 gene in 146 pediatric patients treated with l-asparaginase...
2015: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/25573198/effect-of-premedications-in-a-murine-model-of-asparaginase-hypersensitivity
#10
Christian A Fernandez, Colton Smith, Seth E Karol, Laura B Ramsey, Chengcheng Liu, Ching-Hon Pui, Sima Jeha, William E Evans, Fred D Finkelman, Mary V Relling
A murine model was developed that recapitulates key features of clinical hypersensitivity to Escherichia coli asparaginase. Sensitized mice developed high levels of anti-asparaginase IgG antibodies and had immediate hypersensitivity reactions to asparaginase upon challenge. Sensitized mice had complete inhibition of plasma asparaginase activity (P = 4.2 × 10(-13)) and elevated levels of mouse mast cell protease 1 (P = 6.1 × 10(-3)) compared with nonsensitized mice. We investigated the influence of pretreatment with triprolidine, cimetidine, the platelet activating factor (PAF) receptor antagonist CV-6209 [2-(2-acetyl-6-methoxy-3,9-dioxo-4,8-dioxa-2,10-diazaoctacos-1-yl)-1-ethyl-pyridinium chloride], or dexamethasone on the severity of asparaginase-induced allergies...
March 2015: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/25418987/peg-asparaginase-allergy-in-children-with-acute-lymphoblastic-leukemia-in-the-nopho-all2008-protocol
#11
RANDOMIZED CONTROLLED TRIAL
Louise Tram Henriksen, Arja Harila-Saari, Ellen Ruud, Jonas Abrahamsson, Kaie Pruunsild, Goda Vaitkeviciene, Ólafur Gísli Jónsson, Kjeld Schmiegelow, Mats Heyman, Henrik Schrøder, Birgitte Klug Albertsen
BACKGROUND: L-Asparaginase is an effective drug in the treatment of childhood acute lymphoblastic leukemia (ALL). The use of L-asparaginase may be limited by serious adverse events of which allergy is the most frequent. The objective of this study was to describe the clinical aspects of PEG-asparaginase allergy in children treated according to the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol. PROCEDURE: Children (1-17 years) enrolled in the NOPHO ALL2008 protocol between July 2008 and August 2011, who developed PEG-asparaginase allergy were identified through the NOPHO ALL2008 toxicity registry...
March 2015: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/25393506/clinical-application-of-asparaginase-activity-levels-following-treatment-with-pegaspargase
#12
Archie Bleyer, Barbara L Asselin, Susannah E Koontz, Stephen P Hunger
Asparaginase, an enzyme used to treat acute lymphoblastic leukemia and related forms of nonHodgkin lymphoma, depletes asparagine, which leads to lymphoblast cell death. Unlike most chemotherapeutic agents, asparaginase is a foreign protein that can result in clinical allergy and/or silent hypersensitivity with production of neutralizing antibodies that inactivate asparaginase. In North America, asparaginase activity levels can now be obtained via a commercially available assay, for therapeutic drug monitoring and investigation of potential allergic reactions...
June 2015: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/25150254/the-toxicity-of-very-prolonged-courses-of-pegasparaginase-or-erwinia-asparaginase-in-relation-to-asparaginase-activity-with-a-special-focus-on-dyslipidemia
#13
Wing H Tong, Rob Pieters, Hester A de Groot-Kruseman, Wim C J Hop, Joachim Boos, Wim J E Tissing, Inge M van der Sluis
We prospectively studied the incidence and clinical course of hypertriglyceridemia and hypercholesterolemia during very prolonged use of asparaginase in relation to levels of asparaginase activity in children with acute lymphoblastic leukemia. We also evaluated the incidence of pancreatitis, thrombosis, hyperammonemia and central neurotoxicity and their association with asparaginase activity levels. Eighty-nine patients were treated according to the Dutch Childhood Oncology Group Acute Lymphoblastic Leukemia 10 medium-risk intensification protocol, which includes 15 doses of PEGasparaginase (2,500 IU/m(2)) over 30 weeks...
November 2014: Haematologica
https://www.readbyqxmd.com/read/25147374/asparaginase-allergies-it-s-all-in-the-genes
#14
COMMENT
Meir Wetzler
No abstract text is available yet for this article.
August 21, 2014: Blood
https://www.readbyqxmd.com/read/24970932/hla-drb1-07-01-is-associated-with-a-higher-risk-of-asparaginase-allergies
#15
MULTICENTER STUDY
Christian A Fernandez, Colton Smith, Wenjian Yang, Mihir Daté, Donald Bashford, Eric Larsen, W Paul Bowman, Chengcheng Liu, Laura B Ramsey, Tamara Chang, Victoria Turner, Mignon L Loh, Elizabeth A Raetz, Naomi J Winick, Stephen P Hunger, William L Carroll, Suna Onengut-Gumuscu, Wei-Min Chen, Patrick Concannon, Stephen S Rich, Paul Scheet, Sima Jeha, Ching-Hon Pui, William E Evans, Meenakshi Devidas, Mary V Relling
Asparaginase is a therapeutic enzyme used to treat leukemia and lymphoma, with immune responses resulting in suboptimal drug exposure and a greater risk of relapse. To elucidate whether there is a genetic component to the mechanism of asparaginase-induced immune responses, we imputed human leukocyte antigen (HLA) alleles in patients of European ancestry enrolled on leukemia trials at St. Jude Children's Research Hospital (n = 541) and the Children's Oncology Group (n = 1329). We identified a higher incidence of hypersensitivity and anti-asparaginase antibodies in patients with HLA-DRB1*07:01 alleles (P = 7...
August 21, 2014: Blood
https://www.readbyqxmd.com/read/24907114/polymorphisms-of-asparaginase-pathway-and-asparaginase-related-complications-in-children-with-acute-lymphoblastic-leukemia
#16
Mohsen Ben Tanfous, Bahram Sharif-Askari, Francesco Ceppi, Haithem Laaribi, Vincent Gagné, Julie Rousseau, Malgorzata Labuda, Lewis B Silverman, Stephen E Sallan, Donna Neuberg, Jeffery L Kutok, Daniel Sinnett, Caroline Laverdière, Maja Krajinovic
PURPOSE: Asparaginase (ASNase) is a standard and critical component in the therapy of childhood acute lymphoblastic leukemia (ALL), but it is also associated with several toxicities. EXPERIMENTAL DESIGN: We recently reported the results of an association study between ASNase pathway genes and event-free survival (EFS) in childhood patients with ALL. The same polymorphisms were interrogated here in relation to allergies, pancreatitis, and thrombotic events following treatment with E...
January 15, 2015: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/24829072/pharmacology-immunogenicity-and-efficacy-of-a-novel-pegylated-recombinant-erwinia-chrysanthemi-derived-l-asparaginase
#17
Wei-Wen Chien, Soraya Allas, Nicolas Rachinel, Pierre Sahakian, Michel Julien, Céline Le Beux, Claire-Emmanuelle Lacroix, Thierry Abribat, Gilles Salles
Bacterial L-asparaginase (ASNase), hydrolyzing L-asparagine (Asn), is an indispensable component used in the treatment of acute lymphoblastic leukemia (ALL) and certain lymphoma entities. Native Erwinia chrysanthemi-derived ASNase (n-crisantaspase) has been approved as a second-line drug for treating patients exhibiting allergy syndromes to native and pegylated Escherichia coli-derived ASNase (EC-ASNase). However, it still induces hypersensitivity in at least 17 % of treated patients. In the present study, we investigated the pharmacological activity, immunogenicity and anti-leukemic activity of a new pegylated recombinant crisantaspase (PEG-r-crisantaspase)...
October 2014: Investigational New Drugs
https://www.readbyqxmd.com/read/24498943/comparison-of-allergic-reactions-to-intravenous-and-intramuscular-pegaspargase-in-children-with-acute-lymphoblastic-leukemia
#18
COMPARATIVE STUDY
William C Petersen, Dana Clark, Stacy L Senn, W Thomas Cash, Scott E Gillespie, Courtney E McCracken, Frank G Keller, Glen Lew
Pegaspargase (PEG) is a standard component of therapy for pediatric acute lymphoblastic leukemia (ALL). Because PEG preparations are bacterially derived, they are highly immunogenic. PEG has traditionally been delivered intramuscularly (IM), but over the last several years, more PEG has been given intravenously (IV) in order to provide a less painful and more convenient means of delivery. However, there are limited data comparing allergic reactions between IV and IM PEG recipients, especially in a large cohort of patients...
May 2014: Pediatric Hematology and Oncology
https://www.readbyqxmd.com/read/24449211/a-prospective-study-on-drug-monitoring-of-pegasparaginase-and-erwinia-asparaginase-and-asparaginase-antibodies-in-pediatric-acute-lymphoblastic-leukemia
#19
Wing H Tong, Rob Pieters, Gertjan J L Kaspers, D Maroeska W M te Loo, Marc B Bierings, Cor van den Bos, Wouter J W Kollen, Wim C J Hop, Claudia Lanvers-Kaminsky, Mary V Relling, Wim J E Tissing, Inge M van der Sluis
This study prospectively analyzed the efficacy of very prolonged courses of pegylated Escherichia coli asparaginase (PEGasparaginase) and Erwinia asparaginase in pediatric acute lymphoblastic leukemia (ALL) patients. Patients received 15 PEGasparaginase infusions (2500 IU/m(2) every 2 weeks) in intensification after receiving native E coli asparaginase in induction. In case of allergy to or silent inactivation of PEGasparaginase, Erwinia asparaginase (20 000 IU/m(2) 2-3 times weekly) was given. Eighty-nine patients were enrolled in the PEGasparaginase study...
March 27, 2014: Blood
https://www.readbyqxmd.com/read/23794007/asparaginase-erwinia-chrysanthemi-erwinaze%C3%A2-a-guide-to-its-use-in-acute-lymphoblastic-leukemia-in-the-usa
#20
Gillian M Keating
Asparaginase Erwinia chrysanthemi (Erwinaze®) is approved in the USA for use in patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to Escherichia coli-derived asparaginase. The approved regimen of intramuscular Erwinaze® was associated with sustained, clinically meaningful asparaginase activity in patients with ALL who had to discontinue treatment with pegaspargase (a pegylated formulation of E. coli asparaginase) because of hypersensitivity. Another study revealed that development of E...
August 2013: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
keyword
keyword
61752
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"